NEW YORK, July 18 - Privately held genomic-tool company Genteon and the Institute for Genetic Medicine at the University of Southern California today said they will partner to study prostate cancer.
The USC team, led by Juergen Reichardt of the Keck School of Medicine, will get access to Genteon's Capella 400 genetic-analysis system in order to study genomic mutations and gene expression in tumor samples.
The Capella system, which made its debut in October 2001, is Genteon's first I-tool. It is an automated 384-capillary electrophoresis system equipped with dynamic fluorescent detection.
Click here for more information.